Financial Performance - First quarter net sales were $1.909 billion, representing a 1.1% increase year-over-year and a 2.3% increase on a constant currency basis[2]. - Net earnings for the first quarter were $182.0 million, with adjusted net earnings of $361.1 million[2]. - Diluted earnings per share were $0.91, while adjusted diluted earnings per share were $1.81[3]. - Total sales in the United States were $1.113 billion, a 1.3% increase, while international sales were $795.5 million, a 0.7% increase[10]. - Operating profit for Q1 2025 was $292.3 million, up from $265.9 million in Q1 2024, reflecting a growth of 9.5%[34]. - Net earnings attributable to Zimmer Biomet Holdings, Inc. for Q1 2025 were $182.0 million, compared to $172.4 million in Q1 2024, representing a 4.1% increase[34]. - Free cash flow for Q1 2025 was $278.5 million, significantly higher than $90.9 million in Q1 2024, marking an increase of 206.6%[49]. - Net cash provided by operating activities increased to $382.8 million in Q1 2025 from $228.0 million in Q1 2024, a growth of 77.9%[49]. - Operating profit margin improved to 15.3% in Q1 2025 from 14.1% in Q1 2024[52]. - Adjusted operating profit for Q1 2025 was $500.5 million, down from $539.4 million in Q1 2024, reflecting a decrease of 7.2%[52]. Revenue Guidance and Projections - The company updated its full-year 2025 reported revenue guidance to a range of 5.7% to 8.2% growth, reflecting the impact of the Paragon 28 acquisition[12]. - The company reported a projected full-year 2025 revenue change of 5.7% to 8.2%, with an organic constant currency revenue change of 3.0% to 5.0%[42]. - The company’s projected revenue growth is impacted by a foreign currency exchange effect of 0.0% to 0.5% for the full year 2025[42]. Acquisitions and Market Position - The acquisition of Paragon 28, focused on the foot and ankle orthopedic segment, strengthens the company's position in a high-growth market[7]. - U.S. hips sales showed momentum, driven by new products like the Z1™ Triple-Taper Femoral Hip System and the HAMMR® Automated Hip Surgical Impactor System[5]. - The company received FDA clearance for the Persona® Revision SoluTion™ Femur, expected to be commercially available in Q3 2025[7]. Cost and Expenses - Research and development expenses for Q1 2025 were $110.6 million, slightly up from $107.9 million in Q1 2024[34]. - The cost of products sold, excluding intangible asset amortization, was $549.8 million for Q1 2025, compared to $512.3 million in Q1 2024, reflecting an increase of 7.3%[51]. - Adjusted gross profit for Q1 2025 was $1,365.5 million, down from $1,378.0 million in Q1 2024, indicating a decrease of 0.9%[51]. - The gross margin for Q1 2025 was 63.3%, compared to 65.4% in Q1 2024, showing a decline of 2.1 percentage points[51]. - The company incurred $36.0 million in restructuring and other cost reduction initiatives in Q1 2025, down from $124.4 million in Q1 2024[34]. - The interest expense for Q1 2025 was $66.2 million, compared to $50.7 million in Q1 2024, indicating an increase in financing costs[34]. - The company incurred $151.0 million in intangible asset amortization for Q1 2025, compared to $142.1 million in Q1 2024, reflecting an increase of 6.3%[51]. Assets and Debt - Cash and cash equivalents increased significantly to $1,384.5 million as of March 31, 2025, from $525.5 million at the end of 2024[37]. - The company’s total assets increased to $22,183.9 million as of March 31, 2025, compared to $21,365.3 million at the end of 2024[37]. - Total debt as of March 31, 2025, was $7,176.3 million, an increase from $6,204.6 million as of December 31, 2024[55]. - Net debt increased to $5,791.8 million as of March 31, 2025, compared to $5,679.1 million as of December 31, 2024[55]. Corporate Recognition - The company was named one of the 2025 World's Most Ethical Companies by Ethisphere[11].

Wall Street analysts forecast that Zimmer Biomet (ZBH) will report quarterly earnings of $1.77 per share in its upcoming release, pointing to a year-over-year decline of 8.8%. It is anticipated that revenues will amount to $1.89 billion, exhibiting an increase of 0.2% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before ...

Zimmer Biomet Holdings, Inc. (ZBH) is scheduled to report first-quarter 2025 results on May 5, before market open.In the last reported quarter, the company’s earnings of $2.31 surpassed the Zacks Consensus Estimate by 0.4%. ZBH beat on earnings in three of the trailing four quarters and missed on one occasion, the average earnings surprise being 1.28%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar).Q1 Estimates for ZBHThe Zacks Consensus Estimate for revenues is pegged at $1.89 bil ...

报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月21日，全球骨科巨头捷迈邦美Zimmer Biomet（纽约证券交易所代码：ZBH）宣布，已完成 对Paragon 28的收购，该交易价值 12亿美元 （合约87亿人民币）。Paragon 28拥有广泛的手术产品 和系统，涵盖足部和踝部所有主要领域，包括骨折和创伤、畸形矫正以及关节置换。 # 收购分析 前情回顾 2025年1月，Zimmer Biomet同意收购Paragon 28， 将以 每股13美元 的价格收购Paragon 28的所有流 通股。 该交易包括每股13美元的现金预付款和每股高达1美元的或有价值权（CVR） ，与2026财年的具 体收入里程碑挂钩。 这一价格较Paragon周二收盘价12美元略有溢价；其股价在最近的10月份还曾跌破5美元。 Needham的分析人士在给投资者的报告中写道，他们长期以来一直认为Paragon 28 是潜在的被收购目标， 并对捷迈邦美支出的小幅溢价感到"惊讶"。分析人士预计，捷迈邦美可能会进行更多收购，收购方向可能超 出骨科领域范围。 ...

Core Viewpoint - Zimmer Biomet has completed the acquisition of Paragon 28, enhancing its position in the rapidly growing foot and ankle orthopedic market [1][5]. Group 1: Acquisition Details - The acquisition was finalized on April 21, 2025, under a merger agreement dated January 28, 2025 [5]. - Each outstanding common share of Paragon 28 was converted into $13.00 in cash and a contingent value right (CVR) worth up to $1.00 per share based on revenue milestones [6]. - Following the acquisition, Paragon 28 became a wholly-owned subsidiary of Zimmer Biomet, and its shares were delisted from the New York Stock Exchange [6][7]. Group 2: Strategic Benefits - The transaction strengthens Zimmer Biomet's offerings in the foot and ankle segment, leveraging Paragon 28's technology and sales organization [3]. - It complements Zimmer Biomet's existing fracture, trauma, and joint replacement portfolios, creating a dedicated sales channel for foot and ankle products [3]. - The acquisition is expected to drive growth in a ~$5 billion foot and ankle industry, which is projected to grow at high-single digits [4]. Group 3: Market Positioning - The acquisition enhances Zimmer Biomet's global footprint and infrastructure, facilitating adoption and growth in both U.S. and international markets [4]. - It accelerates penetration into the fast-growing Ambulatory Surgery Center (ASC) space, aligning with industry trends [4].

报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月，据medical design and outsourcing网站报道，捷迈邦美Zimmer Biomet披露了其首席执行官、其他高管以及普通员工的薪酬变动，预计均有 所上涨。与此同时，GE医疗公布其高管以及普通员工的薪酬均有所下降。 2024年Zimmer Biomet 薪酬最高的高管是总裁兼首席执行官 Ivan Tornos，年薪为 1500万美元 ，其中包括120万美元的薪水、1180万美元的股票奖励和170万美 元的奖金。Ivan Tornos还获得了价值26万美元各类补贴，总薪酬比前一年的1020万美元 上 涨47%。 Suketu Upadhyay：首席财务官兼财务、运营以及供应链执行副总裁 # 捷迈邦美高管 薪酬 排名 Ivan Tornos：总裁兼首席执行官 年薪为 5 90万美元 ，其中包括87.6万美元的薪水、400万美元的股票奖励和82.09万美元的奖金等，此外获得价值18万美元左右的各类补贴，总薪酬较上 一年的1040万美元 下降43%。 Wilfre ...

报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月，据medical design and outsourcing网站报道，捷迈邦美Zimmer Biomet披露了其首席执行官、其他高管以及普通员工的薪酬变动，预计均有 所上涨。与此同时，GE医疗公布其高管以及普通员工的薪酬均有所下降。 2024年Zimmer Biomet 薪酬最高的高管是总裁兼首席执行官 Ivan Tornos，年薪为 1500万美元 ，其中包括120万美元的薪水、1180万美元的股票奖励和170万美 元的奖金。Ivan Tornos还获得了价值26万美元各类补贴，总薪酬比前一年的1020万美元 上 涨47%。 Suketu Upadhyay：首席财务官兼财务、运营以及供应链执行副总裁 # 捷迈邦美高管 薪酬 排名 Ivan Tornos：总裁兼首席执行官 年薪为 5 90万美元 ，其中包括87.6万美元的薪水、400万美元的股票奖励和82.09万美元的奖金等，此外获得价值18万美元左右的各类补贴，总薪酬较上 一年的1040万美元 下降43%。 Wilfre ...

WARSAW, Ind., April 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Monday, May 5, 2025, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the ...

Zimmer Biomet’s (ZBH) strategic priorities, new product launches and focus on international expansion bolster our confidence in this stock. Yet, the difficult macroeconomic situation and leveraged capital structure are concerning. The stock carries a Zacks Rank #3 (Hold).Favorable Factors For ZBHDespite challenging market conditions in the form of pricing pressure, the last few quarters witnessed gradual stability in the global musculoskeletal market with better-than-expected sales growth in certain geograp ...

Expanding Thoracic Portfolio With the CE Mark, Zimmer Biomet will make the RibFix Advantage Fixation System available in the European Economic Area (EEA) and other markets that recognize the CE Mark. RibFix Advantage Fixation System For more information on the RibFix Advantage Fixation System watch the animation. About Zimmer Biomet With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues t ...